Condition: Clinical Suspicion of Prostate Cancer · Sponsor: IRCCS San Raffaele
This project aims to evaluate the role of fully hybrid PET/MRI with 18FPSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa). Our main hypothesis is that adding 18F-PSMA PET to mpMRI prior to biopsy, will reduce the number of false negative findings, while at the same time, allowing also to reduce the number of unnecessary prostate biopsies in patients with low-risk, clinically indolent PCa.
This description comes directly from the study's public registry record.
Maria Picchio, MD · 02-26436117 · Picchio.maria@hsr.it
Rachele Di Donato, PhD · 02-26433639 · didonato.rachele@hsr.it
Always discuss trial participation with your own doctor first.
| U.O. of Nuclear Medicine, ,Ospedale San Raffaele | Milan, Milano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06305390